Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Interest & Investment Income: 2021-2025

Historic Interest & Investment Income for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $10.9 million.

  • Janux Therapeutics' Interest & Investment Income rose 40.54% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year increase of 66.73%. This contributed to the annual value of $29.9 million for FY2024, which is 103.28% up from last year.
  • Latest data reveals that Janux Therapeutics reported Interest & Investment Income of $10.9 million as of Q3 2025, which was down 2.86% from $11.3 million recorded in Q2 2025.
  • Janux Therapeutics' Interest & Investment Income's 5-year high stood at $11.4 million during Q1 2025, with a 5-year trough of $46,000 in Q2 2021.
  • Its 3-year average for Interest & Investment Income is $7.1 million, with a median of $7.8 million in 2024.
  • Data for Janux Therapeutics' Interest & Investment Income shows a peak YoY spiked of 2,874.32% (in 2022) over the last 5 years.
  • Janux Therapeutics' Interest & Investment Income (Quarterly) stood at $74,000 in 2021, then skyrocketed by 2,874.32% to $2.2 million in 2022, then soared by 98.96% to $4.4 million in 2023, then surged by 101.10% to $8.8 million in 2024, then skyrocketed by 40.54% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q3 2025, $11.3 million for Q2 2025, and $11.4 million during Q1 2025.